XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue [1] $ 427,690 $ 297,057
Expenses    
Cost of revenue [1] 310,475 219,739
Selling, general and administrative expenses [1] 89,726 58,932
Depreciation and amortization expenses 29,275 15,106
Change in fair value of contingent consideration 8,569 6,078
Total operating expenses 438,045 299,855
Operating loss (10,355) (2,798)
Interest income 1,060 117
Interest expense (12,895) (2,241)
Gain from equity method investees 423 596
Change in tax receivable agreement liability (66,184) 0
Other income (expense), net (220) 178
Loss before income taxes (88,171) (4,148)
Provision for (benefit from) income taxes (68,189) 1,202
Loss before preferred dividends and accretion of Series A Preferred Stock (19,982) (5,350)
Dividends and accretion of Series A Preferred Stock (6,276) 0
Net loss attributable to common shareholders of Evolent Health, Inc - Basic (26,258) (5,350)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (26,258) $ (5,350)
Loss per common share    
Basic (in dollars per share) $ (0.24) $ (0.06)
Diluted (in dollars per share) $ (0.24) $ (0.06)
Weighted-average common shares outstanding    
Basic (in shares) 107,783 89,509
Diluted (in shares) 107,783 89,509
Comprehensive loss    
Net income (loss) $ (26,258) $ (5,350)
Other comprehensive loss, net of taxes, related to:    
Foreign currency translation adjustment 56 (132)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (26,202) $ (5,482)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.